Screener
ADMA Biologics ADMA Gain On Sale Of Investments
Gain On Sale Of Investments at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:GainOnSaleOfInvestments.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Three Months ended June 30, 2026 | Three Months ended June 30, 2025 | Six Months ended June 30, 2026 | Six Months ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 6,014 | 1,031 | 8,611 | 1,858 |
| Plasma center operating expenses | 1,026 | 1,152 | 2,088 | 2,438 |
| Amortization of intangible assets | 55 | 32 | 110 | 57 |
| Gain on sale of plasma centers | - | - | (7,980) | - |
| Selling, general and administrative | 26,737 | 22,214 | 53,479 | 46,292 |
| Total operating expenses | 33,832 | 24,429 | 56,308 | 50,645 |
| INCOME FROM OPERATIONS | 52,445 | 42,798 | 110,719 | 77,678 |
| OTHER INCOME (EXPENSE): |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's gain on sale of investments?
- ADMA Biologics (ADMA) reported gain on sale of investments of $0 in Q2 2026.
- What does gain on sale of investments mean?
- Gain On Sale Of Investments
Ask your AI about ADMA Biologics's gain on sale of investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude